Genetic Investigation of Cancer Predisposition

Not yet recruiting

• Conditions: Cancer; Genetic Predisposition

• Registration Number: NCT04620278
• Lead Sponsor: The University of Texas Health Science Center at San Antonio

Brief Summary

Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and/or a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.

Detailed Description

Genetic screening will be performed on DNA (and/or RNA) isolated from collected samples from affected individuals by whole exome sequencing or RNA sequencing using in-house pipeline to identify candidate sequence variants. These variants will be tested for segregation with the phenotype in other relatives (affected/unaffected). Candidate variants will be subjected to additional downstream analysis, to be guided by the actual type of gene/variant.

Study Timeline

• Study First Submitted: 2020-11-05
• Study First Submitted QC: 2020-11-05
• Study First Posted: 2020-11-06
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-11
• Last Update Posted: 2024-12-13
• Study Start: 2025-10
• Primary Completion: 2030-06
• Study Completion: 2035-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Any age

2. Meets at least ONE of the following:

   1. Personal history (with documented diagnosis) of cancer before the age of 50
   2. Personal history of more than one primary cancer
   3. Documented diagnosis of cancer AND family history of that same cancer type or multiple other cancers that do not fit classical criteria of hereditary cancer syndromes
   4. Documented diagnosis of a rare cancer AND family history of rare cancers that do not fit classical criteria of hereditary cancer syndromes
   5. There is the same type of cancer in several generations of a family
   6. Documented diagnosis of multicentric cancers (e.g bilateral cancers in paired organs, or multifocal cancers in single organs) that usually occur as single lesions when presented sporadically
   7. Early onset cancer (before the age of 50, or breast cancer before age 45) AND family history of early onset cancer Capable of providing access to detailed medical records and family history of cancer

Exclusion Criteria

1. Established genetic diagnosis of a known hereditary cancer syndrome that is compatible with the clinical presentation
2. Incarcerated

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identification of somatic (tumor only) mutation	through study completion- approximately 6-12 months	Genetic screen detects a mutation that is likely responsible for tumor development
Identification of Rare Genetic Variant in family members	through study completion- approximately 6-12 months	Genetic screen detects a mutation that is likely responsible for tumor development
Identification of Rare Genetic Variant	through study completion- approximately 6-12 months	Genetic screen detects a mutation that is likely responsible for tumor development

Secondary Outcome Measures

Name	Time	Method
Identification of clinical spectrum of the disease in families	through study completion- approximately 6-12 months	Genetic and clinical analysis reveals clinical features not previously assigned to the disease

Trial Locations

Locations (1)

University of Texas Health Science Center; 🇺🇸 San Antonio, Texas, United States